30 years of dynorphins - New insights on their functions in neuropsychiatric diseases

Pharmacology and Therapeutics

Volumn 123, Issue 3, 2009, Pages 353-370

  Schwarzer, Christoph ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Anxiety; Depression; Epilepsy; Opioids; Schizophrenia; Stress

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DELTA OPIATE RECEPTOR; DESIPRAMINE; DIAZEPAM; DOPAMINE; DYNORPHIN; DYNORPHIN A [1-8][1 (N METHYLTYROSINE) 7 (N METHYLARGININE) 8 DEXTRO LEUCINE N ETHYLAMIDE]; ENADOLINE; HALOPERIDOL; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; KAPPA OPIATE RECEPTOR ANTAGONIST; MESSENGER RNA; MU OPIATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; NIRAVOLINE; PHENOBARBITAL; PHENYTOIN; PRODYNORPHIN; PROENKEPHALIN; PROOPIOMELANOCORTIN; SEROTONIN; SPIRADOLINE; UNINDEXED DRUG; ZUCLOPENTHIXOL;

ADDICTION; ANTICONVULSANT ACTIVITY; ANXIETY; ANXIETY DISORDER; DEPRESSION; DOPAMINERGIC TRANSMISSION; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; DRUG WITHDRAWAL; DYSPHORIA; EMOTIONALITY; EPILEPSY; EPILEPTOGENESIS; HORMONE ACTION; HORMONE RECEPTOR INTERACTION; HORMONE RELEASE; HUMAN; MENTAL DISEASE; NEUROPROTECTION; NONHUMAN; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROCESSING; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC TRANSMISSION; TRANQUILIZING ACTIVITY; ANIMAL; BRAIN DISEASE; DISEASE MODEL; HISTORY; METABOLISM; MOUSE; PATHOPHYSIOLOGY;

ANIMALS; BRAIN DISEASES; DISEASE MODELS, ANIMAL; DYNORPHINS; HISTORY, 20TH CENTURY; HUMANS; MENTAL DISORDERS; MICE; SUBSTANCE-RELATED DISORDERS;

EID: 67849101645     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2009.05.006     Document Type: Review

References (302)

1. Aradi I., Santhakumar V., Chen K., and Soltesz I. Postsynaptic effects of GABAergic synaptic diversity: regulation of neuronal excitability by changes in IPSC variance. Neuropharmacology 43 (2002) 511-522
2. Arvidsson U., Riedl M., Chakrabarti S., Vulchanova L., Lee J.H., Nakano A.H., et al. The kappa-opioid receptor is primarily postsynaptic: combined immunohistochemical localization of the receptor and endogenous opioids. Proc Natl Acad Sci USA 92 (1995) 5062-5066
3. Bakalkin G., Yakovleva T., and Terenius L. Prodynorphin gene expression relates to NF-kappa B factors. Brain Res Mol Brain Res 24 (1994) 301-312
4. Bakshi R., and Faden A.I. Competitive and non-competitive NMDA antagonists limit dynorphin A-induced rat hindlimb paralysis. Brain Res 507 (1990) 1-5
5. Bale T.L., Contarino A., Smith G.W., Chan R., Gold L.H., Sawchenko P.E., et al. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet 24 (2000) 410-414
6. Bals-Kubik R., Ableitner A., Herz A., and Shippenberg T.S. Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J Pharmacol Exp Ther 264 (1993) 489-495
7. Banks S.J., Eddy K.T., Angstadt M., Nathan P.J., and Phan K.L. Amygdala-frontal connectivity during emotion regulation. Soc Cogn Affect Neurosci 2 (2007) 303-312
8. Barber A., and Gottschlich R. Novel developments with selective, non-peptidic kappa-opioid receptor agonists. Expert Opin Investig Drugs 6 (1997) 1351-1368
9. Barg J., Belcheva M.M., Rowinski J., and Coscia C.J. Kappa-opioid agonist modulation of [3H]thymidine incorporation into DNA: evidence for the involvement of pertussis toxin-sensitive G protein-coupled phosphoinositide turnover. J Neurochem 60 (1993) 1505-1511
10. Barr J., and Van Bockstaele E.J. Vesicular glutamate transporter-1 colocalizes with endogenous opioid peptides in axon terminals of the rat locus coeruleus. Anat Rec A Discov Mol Cell Evol Biol 284 (2005) 466-474
11. Beckstead R.M., Domesick V.B., and Nauta W.J. Efferent connections of the substantia nigra and ventral tegmental area in the rat. Brain Res 175 (1979) 191-217
12. Belcheva M.M., Vogel Z., Ignatova E., Avidor-Reiss T., Zippel R., Levy R., et al. Opioid modulation of extracellular signal-regulated protein kinase activity is ras-dependent and involves Gbetagamma subunits. J Neurochem 70 (1998) 635-645
13. Ben-Ari Y. Cell death and synaptic reorganizations produced by seizures. Epilepsia 42 Suppl 3 (2001) 5-7
14. Berman Y., Mzhavia N., Polonskaia A., Furuta M., Steiner D.F., Pintar J.E., et al. Defective prodynorphin processing in mice lacking prohormone convertase PC2. J Neurochem 75 (2000) 1763-1770
15. Bilkei-Gorzo A., Racz I., Michel K., Mauer D., Zimmer A., Klingmuller D., et al. Control of hormonal stress reactivity by the endogenous opioid system. Psychoneuroendocrinology 33 (2008) 425-436
16. Blednov Y.A., Walker D., Martinez M., and Harris R.A. Reduced alcohol consumption in mice lacking preprodynorphin. Alcohol 40 (2006) 73-86
17. Bortolato M., and Solbrig M.V. The price of seizure control: dynorphins in interictal and postictal psychosis. Psychiatry Res 151 (2007) 139-143
18. Bortolato M., Aru G.N., Frau R., Orru M., Fa M., Manunta M., et al. Kappa opioid receptor activation disrupts prepulse inhibition of the acoustic startle in rats. Biol Psychiatry 57 (2005) 1550-1558
19. Broom D.C., Jutkiewicz E.M., Folk J.E., Traynor J.R., Rice K.C., and Woods J.H. Convulsant activity of a non-peptidic delta-opioid receptor agonist is not required for its antidepressant-like effects in Sprague-Dawley rats. Psychopharmacology (Berl) 164 (2002) 42-48
20. Broom D.C., Nitsche J.F., Pintar J.E., Rice K.C., Woods J.H., and Traynor J.R. Comparison of receptor mechanisms and efficacy requirements for delta-agonist-induced convulsive activity and antinociception in mice. J Pharmacol Exp Ther 303 (2002) 723-729
21. Bruchas M.R., Land B.B., Aita M., Xu M., Barot S.K., Li S., et al. Stress-induced p38 mitogen-activated protein kinase activation mediates kappa-opioid-dependent dysphoria. J Neurosci 27 (2007) 11614-11623
22. Bruchas M.R., Macey T.A., Lowe J.D., and Chavkin C. Kappa opioid receptor activation of p38 MAPK is GRK3- and arrestin-dependent in neurons and astrocytes. J Biol Chem 281 (2006) 18081-18089
23. Brunello N., Blier P., Judd L.L., Mendlewicz J., Nelson C.J., Souery D., et al. Noradrenaline in mood and anxiety disorders: basic and clinical studies. Int Clin Psychopharmacol 18 (2003) 191-202
24. Burke M.C., Letts P.A., Krajewski S.J., and Rance N.E. Coexpression of dynorphin and neurokinin B immunoreactivity in the rat hypothalamus: morphologic evidence of interrelated function within the arcuate nucleus. J Comp Neurol 498 (2006) 712-726
25. Burt A.R., Carr I.C., Mullaney I., Anderson N.G., and Milligan G. Agonist activation of p42 and p44 mitogen-activated protein kinases following expression of the mouse delta opioid receptor in Rat-1 fibroblasts: effects of receptor expression levels and comparisons with G-protein activation. Biochem J 320 (1996) 227-235
26. Calogero A.E., Scaccianoce S., Burrello N., Nicolai R., Muscolo L.A., Kling M.A., et al. The kappa-opioid receptor agonist MR-2034 stimulates the rat hypothalamic-pituitary-adrenal axis: studies in vivo and in vitro. J Neuroendocrinol 8 (1996) 579-585
27. Campos D., Jimenez-Diaz L., and Carrion A.M. Ca(2+)-dependent prodynorphin transcriptional derepression in neuroblastoma cells is exerted through DREAM protein activity in a kinase-independent manner. Mol Cell Neurosci 22 (2003) 135-145
28. Canli T., and Lesch K.P. Long story short: the serotonin transporter in emotion regulation and social cognition. Nat Neurosci 10 (2007) 1103-1109
29. Capper-Loup C., and Kaelin-Lang A. Lateralization of dynorphin gene expression in the rat striatum. Neurosci Lett 447 (2008) 106-108
30. Carlezon W.A.J., Beguin C., DiNieri J.A., Baumann M.H., Richards M.R., Todtenkopf M.S., et al. Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther 316 (2006) 440-447
31. Carrion A.M., Link W.A., Ledo F., Mellstrom B., and Naranjo J.R. DREAM is a Ca2+-regulated transcriptional repressor. Nature 398 (1999) 80-84
32. Caudle R.M., and Dubner R. Ifenprodil blocks the excitatory effects of the opioid peptide dynorphin 1-17 on NMDA receptor-mediated currents in the CA3 region of the guinea pig hippocampus. Neuropeptides 32 (1998) 87-95
33. Caudle R.M., and Isaac L. A novel interaction between dynorphin(1-13) and an N-methyl-D-aspartate site. Brain Res 443 (1988) 329-332
34. Cavalleri G.L., Lynch J.M., Depondt C., Burley M.W., Wood N.W., Sisodiya S.M., et al. Failure to replicate previously reported genetic associations with sporadic temporal lobe epilepsy: where to from here?. Brain 128 (2005) 1832-1840
35. Chang K.J., Hazum E., and Cuatrecasas P. Novel opiate binding sites selective for benzomorphan drugs. Proc Natl Acad Sci USA 78 (1981) 4141-4145
36. Chartoff E.H., Papadopoulou M., MacDonald M.L., Parsegian A., Potter D., Konradi C., et al. Desipramine reduces stress-activated dynorphin expression and CREB phosphorylation in NAc tissue. Mol Pharmacol 75 (2009) 704-712
37. Chavkin C., and Goldstein A. Specific receptor for the opioid peptide dynorphin: structure-activity relationships. Proc Natl Acad Sci USA 78 (1981) 6543-6547
38. Chavkin C., James I.F., and Goldstein A. Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science 215 (1982) 413-415
39. Chen Y., Mestek A., Liu J., and Yu L. Molecular cloning of a rat kappa opioid receptor reveals sequence similarities to the mu and delta opioid receptors. Biochem J 295 (1993) 625-628
40. Cheng H.Y., Pitcher G.M., Laviolette S.R., Whishaw I.Q., Tong K.I., Kockeritz L.K., et al. DREAM is a critical transcriptional repressor for pain modulation. Cell 108 (2002) 31-43
41. Clarke S., Zimmer A., Zimmer A.M., Hill R.G., and Kitchen I. Region selective up-regulation of micro-, delta- and kappa-opioid receptors but not opioid receptor-like 1 receptors in the brains of enkephalin and dynorphin knockout mice. Neuroscience 122 (2003) 479-489
42. Code R.A., and Fallon J.H. Some projections of dynorphin-immunoreactive neurons in the rat central nervous system. Neuropeptides 8 (1986) 165-172
43. Comer S.D., Hoenicke E.M., Sable A.I., McNutt R.W., Chang K.J., De Costa B.R., et al. Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice. J Pharmacol Exp Ther 267 (1993) 888-895
44. Coste S.C., Kesterson R.A., Heldwein K.A., Stevens S.L., Heard A.D., Hollis J.H., et al. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat Genet 24 (2000) 403-409
45. Cox B.M., Opheim K.E., Teschemacher H., and Goldstein A. A peptide-like substance from pituitary that acts like morphine.2. Purification and properties. Life Sci 16 (1975) 1777-1782
46. Day R., and Akil H. The posttranslational processing of prodynorphin in the rat anterior pituitary. Endocrinology 124 (1989) 2392-2405
47. Day R., Lazure C., Basak A., Boudreault A., Limperis P., Dong W., et al. Prodynorphin processing by proprotein convertase 2. Cleavage at single basic residues and enhanced processing in the presence of carboxypeptidase activity. J Biol Chem 273 (1998) 829-836
48. de Lanerolle N.C., Brines M.L., Williamson A., Kim J.H., and Spencer D.D. In: Ribak C.E., Gall C.M., and Mody I. (Eds). The dentate gyrus and its role in seizures (1992), Elsevier, Amsterdam 235-250
49. de Lanerolle N.C., Kim J.H., Williamson A., Spencer S.S., Zaveri H.P., Eid T., et al. A retrospective analysis of hippocampal pathology in human temporal lobe epilepsy: evidence for distinctive patient subcategories. Epilepsia 44 (2003) 677-687
50. de Lanerolle N.C., Williamson A., Meredith C., Kim J.H., Tabuteau H., Spencer D.D., et al. Dynorphin and the kappa 1 ligand [3H]U69,593 binding in the human epileptogenic hippocampus. Epilepsy Res 28 (1997) 189-205
51. De Sarro G., Trimarchi G.R., Sinopoli S., Masuda Y., and De Sarro A. Anticonvulsant effects of U-54494A and U-50488H in genetically epilepsy-prone rats and DBA/2 mice: a possible involvement of glycine/NMDA receptor complex. Gen Pharmacol 24 (1993) 439-447
52. DePaoli A.M., Hurley K.M., Yasada K., Reisine T., and Bell G. Distribution of kappa opioid receptor mRNA in adult mouse brain: an in situ hybridization histochemistry study. Mol Cell Neurosci 5 (1994) 327-335
53. Desbonnet L., Waddington J.L., and O'Tuathaigh C.M. Mutant models for genes associated with schizophrenia. Biochem Soc Trans 37 (2009) 308-312
54. Dhawan B.N., Cesselin F., Raghubir R., Reisine T., Bradley P.B., Portoghese P.S., et al. International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev 48 (1996) 567-592
55. Di Chiara G., and Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 85 (1988) 5274-5278
56. Douglass J., Grimes L., Shook J., Lee P.H., and Hong J.S. Systemic administration of kainic acid differentially regulates the levels of prodynorphin and proenkephalin mRNA and peptides in the rat hippocampus. Brain Res Mol Brain Res 9 (1991) 79-86
57. Douglass J., McKinzie A.A., and Pollock K.M. Identification of multiple DNA elements regulating basal and protein kinase A-induced transcriptional expression of the rat prodynorphin gene. Mol Endocrinol 8 (1994) 333-344
58. Douglass J., McMurray C.T., Garrett J.E., Adelman J.P., and Calavetta L. Characterization of the rat prodynorphin gene. Mol Endocrinol 3 (1989) 2070-2078
59. Drake C.T., Terman G.W., Simmons M.L., Milner T.A., Kunkel D.D., Schwartzkroin P.A., et al. Dynorphin opioids present in dentate granule cells may function as retrograde inhibitory neurotransmitters. J Neurosci 14 (1994) 3736-3750
60. Dubner R., and Ruda M.A. Activity-dependent neuronal plasticity following tissue injury and inflammation. Trends Neurosci 15 (1992) 96-103
61. Dupuy A., Lindberg I., Zhou Y., Akil H., Lazure C., Chretien M., et al. Processing of prodynorphin by the prohormone convertase PC1 results in high molecular weight intermediate forms. Cleavage at a single arginine residue. FEBS Lett 337 (1994) 60-65
62. Faden A.I. Dynorphin increases extracellular levels of excitatory amino acids in the brain through a non-opioid mechanism. J Neurosci 12 (1992) 425-429
63. Fallon J.H., and Leslie F.M. Distribution of dynorphin and enkephalin peptides in the rat brain. J Comp Neurol 249 (1986) 293-336
64. Falls D.L. Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 284 (2003) 14-30
65. Fichna J., Janecka A., Piestrzeniewicz M., Costentin J., and do Rego J.C. Antidepressant-like effect of endomorphin-1 and endomorphin-2 in mice. Neuropsychopharmacology 32 (2007) 813-821
66. Filliol D., Ghozland S., Chluba J., Martin M., Matthes H.W., Simonin F., et al. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 25 (2000) 195-200
67. Fischli W., Goldstein A., Hunkapiller M.W., and Hood L.E. Two "big" dynorphins from porcine pituitary. Life Sci 31 (1982) 1769-1772
68. Fischli W., Goldstein A., Hunkapiller M.W., and Hood L.E. Isolation and amino acid sequence analysis of a 4,000-dalton dynorphin from porcine pituitary. Proc Natl Acad Sci U S A 79 (1982) 5435-5437
69. Frey H.H. Effect of mu- and kappa-opioid agonists on the electroconvulsive seizure threshold in mice and antagonism by naloxone and MR 2266. Pharmacol Toxicol 62 (1988) 150-154
70. Fukuda K., Kato S., Morikawa H., Shoda T., and Mori K. Functional coupling of the delta-, mu-, and kappa-opioid receptors to mitogen-activated protein kinase and arachidonate release in Chinese hamster ovary cells. J Neurochem 67 (1996) 1309-1316
71. Gall C. Seizures induce dramatic and distinctly different changes in enkephalin, dynorphin, and CCK immunoreactivities in mouse hippocampal mossy fibers. J Neurosci 8 (1988) 1852-1862
72. Gambardella A., et al. Prodynorphin gene promoter polymorphism and temporal lobe epilepsy. Epilepsia 44 (2003) 1255-1256
73. Gardell L.R., Ossipov M.H., Vanderah T.W., Lai J., and Porreca F. Dynorphin-independent spinal cannabinoid antinociception. Pain 100 (2002) 243-248
74. Garzon J., Sanchez-Blazquez P., Gerhart J., Loh H.H., and Lee N.M. Dynorphin1-13: interaction with other opiate ligand bindings in vitro. Brain Res 302 (1984) 392-396
75. Gauchy C., Desban M., Krebs M.O., Glowinski J., and Kemel M.L. Role of dynorphin-containing neurons in the presynaptic inhibitory control of the acetylcholine-evoked release of dopamine in the striosomes and the matrix of the cat caudate nucleus. Neuroscience 41 (1991) 449-458
76. Goldstein A., Fischli W., Lowney L.I., Hunkapiller M., and Hood L. Porcine pituitary dynorphin: complete amino acid sequence of the biologically active heptadecapeptide. Proc Natl Acad Sci USA 78 (1981) 7219-7223
77. Goldstein A., Tachibana S., Lowney L.I., Hunkapiller M., and Hood L. Dynorphin-(1-13), an extraordinarily potent opioid peptide. Proc Natl Acad Sci USA 76 (1979) 6666-6670
78. Graeff F.G. On serotonin and experimental anxiety. Psychopharmacology (Berl) 163 (2002) 467-476
79. Gramsch C., Hollt V., Pasi A., Mehraein P., and Herz A. Immunoreactive dynorphin in human brain and pituitary. Brain Res 233 (1982) 65-74
80. Graybiel A.M. The basal ganglia: learning new tricks and loving it. Curr Opin Neurobiol 15 (2005) 638-644
81. Halasy K., Racz B., and Maderspach K. Kappa opioid receptors are expressed by interneurons in the CA1 area of the rat hippocampus: a correlated light and electron microscopic immunocytochemical study. J Chem Neuroanat 19 (2000) 233-241
82. Hara Y., Yakovleva T., Bakalkin G., and Pickel V.M. Dopamine D1 receptors have subcellular distributions conducive to interactions with prodynorphin in the rat nucleus accumbens shell. Synapse 60 (2006) 1-19
83. Harrison P.J., and Law A.J. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry 60 (2006) 132-140
84. Harrison M.B., Shumate M.D., and Lothman E.W. Opioid peptide expression in models of chronic temporal lobe epilepsy. Neuroscience 65 (1995) 785-795
85. Heikkila L., Rimon R., and Terenius L. Dynorphin A and substance P in the cerebrospinal fluid of schizophrenic patients. Psychiatry Res 34 (1990) 229-236
86. Heilig M., Koob G.F., Ekman R., and Britton K.T. Corticotropin-releasing factor and neuropeptide Y: role in emotional integration. Trends Neurosci 17 (1994) 80-85
87. Hescheler J., Rosenthal W., Trautwein W., and Schultz G. The GTP-binding protein, Go, regulates neuronal calcium channels. Nature 325 (1987) 445-447
88. Hewlett W.A., and Barchas J.D. Regional interactions of opioid peptides at mu and delta sites in rat brain. Peptides 4 (1983) 853-858
89. Heyliger S.O., Jackson C., Rice K.C., and Rothman R.B. Opioid peptide receptor studies. 10. Nor-BNI differentially inhibits kappa receptor agonist-induced G-protein activation in the guinea pig caudate: further evidence of kappa receptor heterogeneity. Synapse 34 (1999) 256-265
90. Hjelmstad G.O., and Fields H.L. Kappa opioid receptor inhibition of glutamatergic transmission in the nucleus accumbens shell. J Neurophysiol 85 (2001) 1153-1158
91. Hollt V., Haarmann I., Bovermann K., Jerlicz M., and Herz A. Dynorphin-related immunoreactive peptides in rat brain and pituitary. Neurosci Lett 18 (1980) 149-153
92. Hong J.S., McGinty J.F., Lee P.H., Xie C.W., and Mitchell C.L. Relationship between hippocampal opioid peptides and seizures. Prog Neurobiol 40 (1993) 507-528
93. Horan P.J., de Costa B.R., Rice K., Haaseth R.C., Hruby V.J., and Porreca F. Differential antagonism of bremazocine- and U69,593-induced antinociception by quadazocine: further functional evidence of opioid kappa receptor multiplicity in the mouse. J Pharmacol Exp Ther 266 (1993) 926-933
94. Horikawa S., Takai T., Toyosato M., Takahashi H., Noda M., Kakidani H., et al. Isolation and structural organization of the human preproenkephalin B gene. Nature 306 (1983) 611-614
95. Houser C.R. Morphological changes in the dentate gyrus in human temporal lobe epilepsy. Epilepsy Res Suppl 7 (1992) 223-234
96. Houser C.R., Miyashiro J.E., Swartz B.E., Walsh G.O., Rich J.R., and Delgado-Escueta A.V. Altered patterns of dynorphin immunoreactivity suggest mossy fiber reorganization in human hippocampal epilepsy. J Neurosci 10 (1990) 267-282
97. Huge V., Rammes G., Beyer A., Zieglgansberger W., and Azad S.C. Activation of kappa opioid receptors decreases synaptic transmission and inhibits long-term potentiation in the basolateral amygdala of the mouse. Eur J Pain 13 (2009) 124-129
98. Hurd Y.L. Differential messenger RNA expression of prodynorphin and proenkephalin in the human brain. Neuroscience 72 (1996) 767-783
99. Hurd Y.L., Herman M.M., Hyde T.M., Bigelow L.B., Weinberger D.R., and Kleinman J.E. Prodynorphin mRNA expression is increased in the patch vs matrix compartment of the caudate nucleus in suicide subjects. Mol Psychiatry 2 (1997) 495-500
100. Iadarola M.J., Ofri D., and Kleinman J.E. Enkephalin, dynorphin and substance P in postmortem substantia nigra from normals and schizophrenic patients. Life Sci 48 (1991) 1919-1930
101. Iadarola M.J., Shin C., McNamara J.O., and Yang H.Y. Changes in dynorphin, enkephalin and cholecystokinin content of hippocampus and substantia nigra after amygdala kindling. Brain Res 365 (1986) 185-191
102. Jacobson D.A., Cho J., Landa L.R.J., Tamarina N.A., Roe M.W., Buxbaum J.D., et al. Downstream regulatory element antagonistic modulator regulates islet prodynorphin expression. Am J Physiol Endocrinol Metab 291 (2006) E587-E595
103. James I.F., Fischli W., and Goldstein A. Opioid receptor selectivity of dynorphin gene products. J Pharmacol Exp Ther 228 (1984) 88-93
104. Jeub M., Lie A., Blumcke I., Elger C.E., and Beck H. Loss of dynorphin-mediated inhibition of voltage-dependent Ca2+ currents in hippocampal granule cells isolated from epilepsy patients is associated with mossy fiber sprouting. Neuroscience 94 (1999) 465-471
105. Jin W., Lee N.M., Loh H.H., and Thayer S.A. Dual excitatory and inhibitory effects of opioids on intracellular calcium in neuroblastoma × glioma hybrid NG108-15 cells. Mol Pharmacol 42 (1992) 1083-1089
106. Jolas T., and Aghajanian G.K. Opioids suppress spontaneous and NMDA-induced inhibitory postsynaptic currents in the dorsal raphe nucleus of the rat in vitro. Brain Res 755 (1997) 229-245
107. Kakidani H., Furutani Y., Takahashi H., Noda M., Morimoto Y., Hirose T., et al. Cloning and sequence analysis of cDNA for porcine beta-neo-endorphin/dynorphin precursor. Nature 298 (1982) 245-249
108. Kanamatsu T., McGinty J.F., Mitchell C.L., and Hong J.S. Dynorphin- and enkephalin-like immunoreactivity is altered in limbic-basal ganglia regions of rat brain after repeated electroconvulsive shock. J Neurosci 6 (1986) 644-649
109. Kanamatsu T., Obie J., Grimes L., McGinty J.F., Yoshikawa K., Sabol S., et al. Kainic acid alters the metabolism of Met5-enkephalin and the level of dynorphin A in the rat hippocampus. J Neurosci 6 (1986) 3094-3102
110. Kanemitsu Y., Hosoi M., Zhu P.J., Weight F.F., Peoples R.W., McLaughlin J.S., et al. Dynorphin A inhibits NMDA receptors through a pH-dependent mechanism. Mol Cell Neurosci 24 (2003) 525-537
111. Karlsson R.M., Choe J.S., Cameron H.A., Thorsell A., Crawley J.N., Holmes A., et al. The neuropeptide Y Y1 receptor subtype is necessary for the anxiolytic-like effects of neuropeptide Y, but not the antidepressant-like effects of fluoxetine, in mice. Psychopharmacology (Berl) 195 (2008) 547-557
112. Kask A., Harro J., von Horsten S., Redrobe J.P., Dumont Y., and Quirion R. The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y. Neurosci Biobehav Rev 26 (2002) 259-283
113. Kawaguchi Y., Wilson C.J., and Emson P.C. Projection subtypes of rat neostriatal matrix cells revealed by intracellular injection of biocytin. J Neurosci 10 (1990) 3421-3438
114. Khachaturian H., Watson S.J., Lewis M.E., Coy D., Goldstein A., and Akil H. Dynorphin immunocytochemistry in the rat central nervous system. Peptides 3 (1982) 941-954
115. Kishimoto T., Radulovic J., Radulovic M., Lin C.R., Schrick C., Hooshmand F., et al. Deletion of crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nat Genet 24 (2000) 415-419
116. Knoll A.T., Meloni E.G., Thomas J.B., Carroll F.I., and Carlezon W.A. Anxiolytic-like effects of {kappa}-opioid receptor antagonists in models of unlearned and learned fear in rats. J Pharmacol Exp Ther 323 (2007) 838-845
117. Koob G.F. A role for brain stress systems in addiction. Neuron 59 (2008) 11-34
118. Kosten T.R., Rounsaville B.J., and Kleber H.D. A 2.5-year follow-up of depression, life crises, and treatment effects on abstinence among opioid addicts. Arch Gen Psychiatry 43 (1986) 733-738
119. Kosterlitz H.W., Paterson S.J., and Robson L.E. Characterization of the kappa-subtype of the opiate receptor in the guinea-pig brain. Br J Pharmacol 73 (1981) 939-949
120. Kovacs K.M., Szakall I., O'Brien D., Wang R., Vinod K.Y., Saito M., et al. Decreased oral self-administration of alcohol in kappa-opioid receptor knock-out mice. Alcohol Clin Exp Res 29 (2005) 730-738
121. Kreibich A., Reyes B.A., Curtis A.L., Ecke L., Chavkin C., Van Bockstaele E.J., et al. Presynaptic inhibition of diverse afferents to the locus ceruleus by kappa-opiate receptors: a novel mechanism for regulating the central norepinephrine system. J Neurosci 28 (2008) 6516-6525
122. Kudryavtseva N.N., Gerrits M.A., Avgustinovich D.F., Tenditnik M.V., and Van Ree J.M. Modulation of anxiety-related behaviors by mu- and kappa-opioid receptor agonists depends on the social status of mice. Peptides 25 (2004) 1355-1363
123. Kuzmin A., Madjid N., Terenius L., Ogren S.O., and Bakalkin G. Big dynorphin, a prodynorphin-derived peptide produces NMDA receptor-mediated effects on memory, anxiolytic-like and locomotor behavior in mice. Neuropsychopharmacology 31 (2006) 1928-1937
124. Lai S.L., Gu Y., and Huang L.Y. Dynorphin uses a non-opioid mechanism to potentiate N-methyl-D-aspartate currents in single rat periaqueductal gray neurons. Neurosci Lett 247 (1998) 115-118
125. Lai J., Luo M.C., Chen Q., Ma S., Gardell L.R., Ossipov M.H., et al. Dynorphin A activates bradykinin receptors to maintain neuropathic pain. Nat Neurosci 9 (2006) 1534-1540
126. Lai J., Ossipov M.H., Vanderah T.W., Malan T.P.J., and Porreca F. Neuropathic pain: the paradox of dynorphin. Mol Interv 1 (2001) 160-167
127. Land B.B., Bruchas M.R., Lemos J.C., Xu M., Melief E.J., and Chavkin C. The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J Neurosci 28 (2008) 407-414
128. Lang P.J., Davis M., and Ohman A. Fear and anxiety: animal models and human cognitive psychophysiology. J Affect Disord 61 (2000) 137-159
129. Larsson M.H., Bayati A., Lindstrom E., and Larsson H. Involvement of kappa-opioid receptors in visceral nociception in mice. Neurogastroenterol Motil 20 (2008) 1157-1164
130. Lason W., Przewlocka B., and Przewlocki R. The effects of excitatory amino acids on proenkephalin and prodynorphin mRNA levels in the hippocampal dentate gyrus of the rat; an in situ hybridization study. Brain Res Mol Brain Res 12 (1992) 243-247
131. Lason W., Przewlocka B., and Przewlocki R. The prodynorphin system in the rat hippocampus is differentially influenced by kainic acid and pentetrazole. Neuroscience 51 (1992) 357-362
132. Laughlin T.M., Larson A.A., and Wilcox G.L. Mechanisms of induction of persistent nociception by dynorphin. J Pharmacol Exp Ther 299 (2001) 6-11
133. Laughlin T.M., Vanderah T.W., Lashbrook J., Nichols M.L., Ossipov M., Porreca F., et al. Spinally administered dynorphin A produces long-lasting allodynia: involvement of NMDA but not opioid receptors. Pain 72 (1997) 253-260
134. Lee P.H., Zhao D., Xie C.W., McGinty J.F., Mitchell C.L., and Hong J.S. Changes of proenkephalin and prodynorphin mRNAs and related peptides in rat brain during the development of deep prepyriform cortex kindling. Brain Res Mol Brain Res 6 (1989) 263-273
135. Lesch K.P. Linking emotion to the social brain. The role of the serotonin transporter in human social behaviour (2007) EMBO Rep 8 Spec No: S24-9
136. Li S., Zhu J., Chen C., Chen Y.W., Deriel J.K., Ashby B., et al. Molecular cloning and expression of a rat kappa opioid receptor. Biochem J 295 (1993) 629-633
137. Lin S., Boey D., Lee N., Schwarzer C., Sainsbury A., and Herzog H. Distribution of prodynorphin mRNA and its interaction with the NPY system in the mouse brain. Neuropeptides 40 (2006) 115-123
138. Loacker S., Sayyah M., Wittmann W., Herzog H., and Schwarzer C. Endogenous dynorphin in epileptogenesis and epilepsy: anticonvulsant net effect via kappa opioid receptors. Brain 130 (2007) 1017-1028
139. Lord J.A., Waterfield A.A., Hughes J., and Kosterlitz H.W. Endogenous opioid peptides: multiple agonists and receptors. Nature 267 (1977) 495-499
140. Lowry C.A., Hale M.W., Evans A.K., Heerkens J., Staub D.R., Gasser P.J., et al. Serotonergic systems, anxiety, and affective disorder: focus on the dorsomedial part of the dorsal raphe nucleus. Ann N Y Acad Sci 1148 (2008) 86-94
141. Ma J., Ye N., Lange N., and Cohen B.M. Dynorphinergic GABA neurons are a target of both typical and atypical antipsychotic drugs in the nucleus accumbens shell, central amygdaloid nucleus and thalamic central medial nucleus. Neuroscience 121 (2003) 991-998
142. Madamba S.G., Schweitzer P., and Siggins G.R. Dynorphin selectively augments the M-current in hippocampal CA1 neurons by an opiate receptor mechanism. J Neurophysiol 82 (1999) 1768-1775
143. Mague S.D., Pliakas A.M., Todtenkopf M.S., Tomasiewicz H.C., Zhang Y., Stevens W.C.J., et al. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther 305 (2003) 323-330
144. Mansour A., Fox C.A., Meng F., Akil H., and Watson S.J. Kappa 1 receptor mRNA distribution in the rat CNS: comparison to kappa receptor binding and prodynorphin mRNA. Mol Cell Neurosci 5 (1994) 124-144
145. Mansour A., Hoversten M.T., Taylor L.P., Watson S.J., and Akil H. The cloned mu, delta and kappa receptors and their endogenous ligands: evidence for two opioid peptide recognition cores. Brain Res 700 (1995) 89-98
146. Mansour A., Watson S.J., and Akil H. Opioid receptors: past, present and future. Trends Neurosci 18 (1995) 69-70
147. Mansson E., Bare L., and Yang D. Isolation of a human kappa opioid receptor cDNA from placenta. Biochem Biophys Res Commun 202 (1994) 1431-1437
148. Marco E.M., Llorente R., Perez-Alvarez L., Moreno E., Guaza C., and Viveros M.P. The kappa-opioid receptor is involved in the stimulating effect of nicotine on adrenocortical activity but not in nicotine induced anxiety. Behav Brain Res 163 (2005) 212-218
149. Margolis E.B., Hjelmstad G.O., Bonci A., and Fields H.L. Kappa-opioid agonists directly inhibit midbrain dopaminergic neurons. J Neurosci 23 (2003) 9981-9986
150. Margolis E.B., Lock H., Chefer V.I., Shippenberg T.S., Hjelmstad G.O., and Fields H.L. Kappa opioids selectively control dopaminergic neurons projecting to the prefrontal cortex. Proc Natl Acad Sci U S A 103 (2006) 2938-2942
151. Margolis E.B., Mitchell J.M., Ishikawa J., Hjelmstad G.O., and Fields H.L. Midbrain dopamine neurons: projection target determines action potential duration and dopamine D(2) receptor inhibition. J Neurosci 28 (2008) 8908-8913
152. Marin S., Marco E., Biscaia M., Fernandez B., Rubio M., Guaza C., et al. Involvement of the kappa-opioid receptor in the anxiogenic-like effect of CP 55,940 in male rats. Pharmacol Biochem Behav 74 (2003) 649-656
153. Marinova Z., Vukojevic V., Surcheva S., Yakovleva T., Cebers G., Pasikova N., et al. Translocation of dynorphin neuropeptides across the plasma membrane. A putative mechanism of signal transmission. J Biol Chem 280 (2005) 26360-26370
154. Martin-Soelch C. Is depression associated with dysfunction of the central reward system?. Biochem Soc Trans 37 (2009) 313-317
155. Martin W.R. History and development of mixed opioid agonists, partial agonists and antagonists. Br J Clin Pharmacol 7 Suppl 3 (1979) 273S-279S
156. Martin W.R., Eades C.G., Thompson J.A., Huppler R.E., and Gilbert P.E. The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197 (1976) 517-532
157. Mathieu-Kia A.M., Fan L.Q., Kreek M.J., Simon E.J., and Hiller J.M. Mu-, delta- and kappa-opioid receptor populations are differentially altered in distinct areas of postmortem brains of Alzheimer's disease patients. Brain Res 893 (2001) 121-134
158. Matsu-ura T., Konishi Y., Aoki T., Naranjo J.R., Mikoshiba K., and Tamura T.A. Seizure-mediated neuronal activation induces DREAM gene expression in the mouse brain. Brain Res Mol Brain Res 109 (2002) 198-206
159. McFadzean I., Lacey M.G., Hill R.G., and Henderson G. Kappa opioid receptor activation depresses excitatory synaptic input to rat locus coeruleus neurons in vitro. Neuroscience 20 (1987) 231-239
160. McGinty J.F., Henriksen S.J., Goldstein A., Terenius L., and Bloom F.E. Dynorphin is contained within hippocampal mossy fibers: immunochemical alterations after kainic acid administration and colchicine-induced neurotoxicity. Proc Natl Acad Sci USA 80 (1983) 589-593
161. McGinty J.F., Kanamatsu T., Obie J., Dyer R.S., Mitchell C.L., and Hong J.S. Amygdaloid kindling increases enkephalin-like immunoreactivity but decreases dynorphin-A-like immunoreactivity in rat hippocampus. Neurosci Lett 71 (1986) 31-36
162. McLaughlin J.P., Marton-Popovici M., and Chavkin C. Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci 23 (2003) 5674-5683
163. McMurray C.T., Pollock K.M., and Douglass J. Cellular and molecular analysis of opioid peptide gene expression. NIDA Res Monogr 126 (1992) 113-131
164. Menendez L., Andres-Trelles F., Hidalgo A., and Baamonde A. Involvement of spinal kappa opioid receptors in a type of footshock induced analgesia in mice. Brain Res 611 (1993) 264-271
165. Meng F., Xie G.X., Thompson R.C., Mansour A., Goldstein A., Watson S.J., et al. Cloning and pharmacological characterization of a rat kappa opioid receptor. Proc Natl Acad Sci USA 90 (1993) 9954-9958
166. Merchenthaler I., Maderdrut J.L., Cianchetta P., Shughrue P., and Bronstein D. In situ hybridization histochemical localization of prodynorphin messenger RNA in the central nervous system of the rat. J Comp Neurol 384 (1997) 211-232
167. Merens W., Willem Van der Does A.J., and Spinhoven P. The effects of serotonin manipulations on emotional information processing and mood. J Affect Disord 103 (2007) 43-62
168. Michelsen K.A., Prickaerts J., and Steinbusch H.W. The dorsal raphe nucleus and serotonin: implications for neuroplasticity linked to major depression and Alzheimer's disease. Prog Brain Res 172 (2008) 233-264
169. Millan M.J., Millan M.H., Czlonkowski A., and Herz A. Contrasting interactions of the locus coeruleus as compared to the ventral noradrenergic bundle with CNS and pituitary pools of vasopressin, dynorphin and related opioid peptides in the rat. Brain Res 298 (1984) 243-252
170. Minamino N., Kangawa K., Chino N., Sakakibara S., and Matsuo H. Beta-neo-endorphin, a new hypothalamic "big" Leu-enkephalin of porcine origin: its purification and the complete amino acid sequence. Biochem Biophys Res Commun 99 (1981) 864-870
171. Minamino N., Kangawa K., Fukuda A., Matsuo H., and Iagarashi M. A new opioid octapeptide related to dynorphin from porcine hypothalamus. Biochem Biophys Res Commun 95 (1980) 1475-1481
172. Moneta M.E., and Hollt V. Perforant path kindling induces differential alterations in the mRNA levels coding for prodynorphin and proenkephalin in the rat hippocampus. Neurosci Lett 110 (1990) 273-278
173. Moore S.D., Madamba S.G., Schweitzer P., and Siggins G.R. Voltage-dependent effects of opioid peptides on hippocampal CA3 pyramidal neurons in vitro. J Neurosci 14 (1994) 809-820
174. Morris B.J., Haarmann I., Kempter B., Hollt V., and Herz A. Localization of prodynorphin messenger rna in rat brain by in situ hybridization using a synthetic oligonucleotide probe. Neurosci Lett 69 (1986) 104-108
175. Morris B.J., Moneta M.E., ten Bruggencate G., and Hollt V. Levels of prodynorphin mRNA in rat dentate gyrus are decreased during hippocampal kindling. Neurosci Lett 80 (1987) 298-302
176. Motta V., Penha K., and Brandao M.L. Effects of microinjections of mu and kappa receptor agonists into the dorsal periaqueductal gray of rats submitted to the plus maze test. Psychopharmacology (Berl) 120 (1995) 470-474
177. Mucha R.F., and Herz A. Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning. Psychopharmacology (Berl) 86 (1985) 274-280
178. Mulder A.H., Wardeh G., Hogenboom F., and Frankhuyzen A.L. Kappa- and delta-opioid receptor agonists differentially inhibit striatal dopamine and acetylcholine release. Nature 308 (1984) 278-280
179. Najavits L.M., Gastfriend D.R., Barber J.P., Reif S., Muenz L.R., Blaine J., et al. Cocaine dependence with and without PTSD among subjects in the National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Am J Psychiatry 155 (1998) 214-219
180. Naranjo J.R., Mellstrom B., Achaval M., and Sassone-Corsi P. Molecular pathways of pain: Fos/Jun-mediated activation of a noncanonical AP-1 site in the prodynorphin gene. Neuron 6 (1991) 607-617
181. Narita M., Kaneko C., Miyoshi K., Nagumo Y., Kuzumaki N., Nakajima M., et al. Chronic pain induces anxiety with concomitant changes in opioidergic function in the amygdala. Neuropsychopharmacology 31 (2006) 739-750
182. Nestler E.J., and Carlezon W.A.J. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 59 (2006) 1151-1159
183. Nguyen T.V., Kosofsky B.E., Birnbaum R., Cohen B.M., and Hyman S.E. Differential expression of c-fos and zif268 in rat striatum after haloperidol, clozapine, and amphetamine. Proc Natl Acad Sci U S A 89 (1992) 4270-4274
184. Nikolarakis K.E., Almeida O.F., Yassouridis A., and Herz A. Presynaptic auto- and allelo-receptor regulation of hypothalamic opioid peptide release. Neuroscience 31 (1989) 269-273
185. Nikoshkov A., Hurd Y.L., Yakovleva T., Bazov I., Marinova Z., Cebers G., et al. Prodynorphin transcripts and proteins differentially expressed and regulated in the adult human brain. FASEB J 19 (2005) 1543-1545
186. Nobre M.J., Ribeiro dos Santos N., Aguiar M.S., and Brandao M.L. Blockade of mu- and activation of kappa-opioid receptors in the dorsal periaqueductal gray matter produce defensive behavior in rats tested in the elevated plus-maze. Eur J Pharmacol 404 (2000) 145-151
187. North R.A., Williams J.T., Surprenant A., and Christie M.J. Mu and delta receptors belong to a family of receptors that are coupled to potassium channels. Proc Natl Acad Sci USA 84 (1987) 5487-5491
188. Pascoe J.E., Williams K.L., Mukhopadhyay P., Rice K.C., Woods J.H., and Ko M.C. Effects of mu, kappa, and delta opioid receptor agonists on the function of hypothalamic-pituitary-adrenal axis in monkeys. Psychoneuroendocrinology 33 (2008) 478-486
189. Peckys D., and Hurd Y.L. Prodynorphin and kappa opioid receptor mRNA expression in the cingulate and prefrontal cortices of subjects diagnosed with schizophrenia or affective disorders. Brain Res Bull 55 (2001) 619-624
190. Pfeiffer A., Brantl V., Herz A., and Emrich H.M. Psychotomimesis mediated by kappa opiate receptors. Science 233 (1986) 774-776
191. Pierce J.P., and Milner T.A. Parallel increases in the synaptic and surface areas of mossy fiber terminals following seizure induction. Synapse 39 (2001) 249-256
192. Pierce J.P., Kurucz O.S., and Milner T.A. Morphometry of a peptidergic transmitter system: dynorphin B-like immunoreactivity in the rat hippocampal mossy fiber pathway before and after seizures. Hippocampus 9 (1999) 255-276
193. Pinnock R.D. A highly selective kappa-opioid receptor agonist, CI-977, reduces excitatory synaptic potentials in the rat locus coeruleus in vitro. Neuroscience 47 (1992) 87-94
194. Pinnock R.D. Activation of kappa-opioid receptors depresses electrically evoked excitatory postsynaptic potentials on 5-HT-sensitive neurones in the rat dorsal raphe nucleus in vitro. Brain Res 583 (1992) 237-246
195. Ploj K., Roman E., Gustavsson L., and Nylander I. Basal levels and alcohol-induced changes in nociceptin/orphanin FQ, dynorphin, and enkephalin levels in C57BL/6J mice. Brain Res Bull 53 (2000) 219-226
196. Privette T.H., and Terrian D.M. Kappa opioid agonists produce anxiolytic-like behavior on the elevated plus-maze. Psychopharmacology (Berl) 118 (1995) 444-450
197. Przewlocka B., Lason W., Machelska H., van Luijtelaar G., Coenen A., and Przewlocki R. Kappa opioid receptor agonists suppress absence seizures in WAG/Rij rats. Neurosci Lett 186 (1995) 131-134
198. Quirion R., and Pert C.B. Dynorphins: similar relative potencies on mu, delta- and kappa-opiate receptors. Eur J Pharmacol 76 (1981) 467-468
199. Racz B., and Halasy K. Kappa opioid receptor is expressed by somatostatin- and neuropeptide Y-containing interneurons in the rat hippocampus. Brain Res 931 (2002) 50-55
200. Raynor K., Kong H., Chen Y., Yasuda K., Yu L., Bell G.I., et al. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol 45 (1994) 330-334
201. Reindl J.D., Rowan K., Carey A.N., Peng X., Neumeyer J.L., and McLaughlin J.P. Antidepressant-like effects of the novel kappa opioid antagonist MCL-144B in the forced-swim test. Pharmacology 81 (2008) 229-235
202. Ressler K.J., and Nemeroff C.B. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 12 Suppl 1 (2000) 2-19
203. Reyes B.A., Chavkin C., and van Bockstaele E.J. Subcellular targeting of kappa-opioid receptors in the rat nucleus locus coeruleus. J Comp Neurol 512 (2009) 419-431
204. Reyes B.A., Drolet G., and Van Bockstaele E.J. Dynorphin and stress-related peptides in rat locus coeruleus: contribution of amygdalar efferents. J Comp Neurol 508 (2008) 663-675
205. Reyes B.A., Johnson A.D., Glaser J.D., Commons K.G., and Van Bockstaele E.J. Dynorphin-containing axons directly innervate noradrenergic neurons in the rat nucleus locus coeruleus. Neuroscience 145 (2007) 1077-1086
206. Rhoads D.L. A longitudinal study of life stress and social support among drug abusers. Int J Addict 18 (1983) 195-222
207. Robertson G.S., and Fibiger H.C. Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46 (1992) 315-328
208. Robertson G.S., Matsumura H., and Fibiger H.C. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 271 (1994) 1058-1066
209. Rocha L., and Maidment N.T. Opioid peptide release in the rat hippocampus after kainic acid-induced status epilepticus. Hippocampus 13 (2003) 472-480
210. Rocha L.L., Evans C.J., and Maidment N.T. Amygdala kindling modifies extracellular opioid peptide content in rat hippocampus measured by microdialysis. J Neurochem 68 (1997) 616-624
211. Romualdi P., Donatini A., Bregola G., Bianchi C., Beani L., Ferri S., et al. Early changes in prodynorphin mRNA and ir-dynorphin A levels after kindled seizures in the rat. Eur J Neurosci 7 (1995) 1850-1856
212. Rosen J.B., Cain C.J., Weiss S.R., and Post R.M. Alterations in mRNA of enkephalin, dynorphin and thyrotropin releasing hormone during amygdala kindling: an in situ hybridization study. Brain Res Mol Brain Res 15 (1992) 247-255
213. Rusin K.I., Giovannucci D.R., Stuenkel E.L., and Moises H.C. Kappa-opioid receptor activation modulates Ca2+ currents and secretion in isolated neuroendocrine nerve terminals. J Neurosci 17 (1997) 6565-6574
214. Sahley T.L., Anderson D.J., and Chernicky C.L. Bi-phasic intensity-dependent opioid-mediated neural amplitude changes in the chinchilla cochlea: partial blockade by an N-Methyl-D-Aspartate (NMDA)-receptor antagonist. Eur J Pharmacol 580 (2008) 100-115
215. Sajdyk T.J., Shekhar A., and Gehlert D.R. Interactions between NPY and CRF in the amygdala to regulate emotionality. Neuropeptides 38 (2004) 225-234
216. Salin P.A., Weisskopf M.G., and Nicoll R.A. A comparison of the role of dynorphin in the hippocampal mossy fiber pathway in guinea pig and rat. J Neurosci 15 (1995) 6939-6945
217. Schepers R.J., Mahoney J.L., Gehrke B.J., and Shippenberg T.S. Endogenous kappa-opioid receptor systems inhibit hyperalgesia associated with localized peripheral inflammation. Pain 138 (2008) 423-439
218. Schwarzer C., and Sperk G. Glutamate-stimulated neuropeptide Y mRNA expression in the rat dentate gyrus: a prominent role of metabotropic glutamate receptors. Hippocampus 8 (1998) 274-288
219. Seidah N.G., Day R., Marcinkiewicz M., and Chretien M. Precursor convertases: an evolutionary ancient, cell-specific, combinatorial mechanism yielding diverse bioactive peptides and proteins. Ann N Y Acad Sci 839 (1998) 9-24
220. Seizinger B.R., Hollt V., and Herz A. Proenkephalin B (prodynorphin)-derived opioid peptides: evidence for a differential processing in lobes of the pituitary. Endocrinology 115 (1984) 662-671
221. Sharifi N., Ament M., Brennan M.B., and Hochgeschwender U. Isolation and characterization of the mouse homolog of the preprodynorphin (Pdyn) gene. Neuropeptides 33 (1999) 236-238
222. Sharifi N., Diehl N., Yaswen L., Brennan M.B., and Hochgeschwender U. Generation of dynorphin knockout mice. Brain Res Mol Brain Res 86 (2001) 70-75
223. Sharma S.K., Klee W.A., and Nirenberg M. Opiate-dependent modulation of adenylate cyclase. Proc Natl Acad Sci U S A 74 (1977) 3365-3369
224. Sheffler D.J., and Roth B.L. Salvinorin A: the "magic mint" hallucinogen finds a molecular target in the kappa opioid receptor. Trends Pharmacol Sci 24 (2003) 107-109
225. Shippenberg T.S., and Herz A. Differential effects of mu and kappa opioid systems on motivational processes. NIDA Res Monogr 75 (1986) 563-566
226. Shippenberg T.S., Zapata A., and Chefer V.I. Dynorphin and the pathophysiology of drug addiction. Pharmacol Ther 116 (2007) 306-321
227. Shirayama Y., Ishida H., Iwata M., Hazama G.I., Kawahara R., and Duman R.S. Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. J Neurochem 90 (2004) 1258-1268
228. Shukla V.K., and Lemaire S. Non-opioid effects of dynorphins: possible role of the NMDA receptor. Trends Pharmacol Sci 15 (1994) 420-424
229. Simmons M.L., Terman G.W., Gibbs S.M., and Chavkin C. L-type calcium channels mediate dynorphin neuropeptide release from dendrites but not axons of hippocampal granule cells. Neuron 14 (1995) 1265-1272
230. Simon H., Le Moal M., and Calas A. Efferents and afferents of the ventral tegmental-A10 region studied after local injection of [3H]leucine and horseradish peroxidase. Brain Res 178 (1979) 17-40
231. Simonato M., and Romualdi P. Dynorphin and epilepsy. Prog Neurobiol 50 (1996) 557-583
232. Simonin F., Gaveriaux-Ruff C., Befort K., Matthes H., Lannes B., Micheletti G., et al. kappa-opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. Proc Natl Acad Sci USA 92 (1995) 7006-7010
233. Simonin F., Valverde O., Smadja C., Slowe S., Kitchen I., Dierich A., et al. Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal. EMBO J 17 (1998) 886-897
234. Slowe S.J., Simonin F., Kieffer B., and Kitchen I. Quantitative autoradiography of mu-,delta- and kappa1 opioid receptors in kappa-opioid receptor knockout mice. Brain Res 818 (1999) 335-345
235. Smith G.W., Aubry J.M., Dellu F., Contarino A., Bilezikjian L.M., Gold L.H., et al. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20 (1998) 1093-1102
236. Solbrig M.V., Adrian R., Baratta J., Lauterborn J.C., and Koob G.F. Kappa opioid control of seizures produced by a virus in an animal model. Brain 129 (2006) 642-654
237. Solbrig M.V., Adrian R., Chang D.Y., and Perng G.C. Viral risk factor for seizures: pathobiology of dynorphin in herpes simplex viral (HSV-1) seizures in an animal model. Neurobiol Dis 23 (2006) 612-620
238. Spanagel R., Herz A., and Shippenberg T.S. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci USA 89 (1992) 2046-2050
239. Stenzel-Poore M.P., Duncan J.E., Rittenberg M.B., Bakke A.C., and Heinrichs S.C. CRH overproduction in transgenic mice: behavioral and immune system modulation. Ann N Y Acad Sci 780 (1996) 36-48
240. Stogmann E., Zimprich A., Baumgartner C., Aull-Watschinger S., Hollt V., and Zimprich F. A functional polymorphism in the prodynorphin gene promotor is associated with temporal lobe epilepsy. Ann Neurol 51 (2002) 260-263
241. Sukhov R.R., Walker L.C., Rance N.E., Price D.L., and Young W.S.r. Opioid precursor gene expression in the human hypothalamus. J Comp Neurol 353 (1995) 604-622
242. Surprenant A., Shen K.Z., North R.A., and Tatsumi H. Inhibition of calcium currents by noradrenaline, somatostatin and opioids in guinea-pig submucosal neurones. J Physiol 431 (1990) 585-608
243. Swanson L.W. The locus coeruleus: a cytoarchitectonic, Golgi and immunohistochemical study in the albino rat. Brain Res 110 (1976) 39-56
244. Takahashi M., Senda T., Tokuyama S., and Kaneto H. Further evidence for the implication of a kappa-opioid receptor mechanism in the production of psychological stress-induced analgesia. Jpn J Pharmacol 53 (1990) 487-494
245. Tanaka M., Yoshida M., Emoto H., and Ishii H. Noradrenaline systems in the hypothalamus, amygdala and locus coeruleus are involved in the provocation of anxiety: basic studies. Eur J Pharmacol 405 (2000) 397-406
246. Tan-No K., Esashi A., Nakagawasai O., Niijima F., Tadano T., Sakurada C., et al. Intrathecally administered big dynorphin, a prodynorphin-derived peptide, produces nociceptive behavior through an N-methyl-D-aspartate receptor mechanism. Brain Res 952 (2002) 7-14
247. Tan-No K., Takahashi H., Nakagawasai O., Niijima F., Sato T., Satoh S., et al. Pronociceptive role of dynorphins in uninjured animals: N-ethylmaleimide-induced nociceptive behavior mediated through inhibition of dynorphin degradation. Pain 113 (2005) 301-309
248. Tao R., and Auerbach S.B. Opioid receptor subtypes differentially modulate serotonin efflux in the rat central nervous system. J Pharmacol Exp Ther 303 (2002) 549-556
249. Telkov M., Geijer T., and Terenius L. Human prodynorphin gene generates several tissue-specific transcripts. Brain Res 804 (1998) 284-295
250. Terman G.W., Drake C.T., Simmons M.L., Milner T.A., and Chavkin C. Opioid modulation of recurrent excitation in the hippocampal dentate gyrus. J Neurosci 20 (2000) 4379-4388
251. Teschemacher H., Opheim K.E., Cox B.M., and Goldstein A. A peptide-like substance from pituitary that acts like morphine.I. Isolation. Life Sci 16 (1975) 1771-1775
252. Timpl P., Spanagel R., Sillaber I., Kresse A., Reul J.M., Stalla G.K., et al. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet 19 (1998) 162-166
253. Toll L., Berzetei-Gurske I.P., Polgar W.E., Brandt S.R., Adapa I.D., Rodriguez L., et al. Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr 178 (1998) 440-466
254. Tortella F.C., Echevarria E., Lipkowski A.W., Takemori A.E., Portoghese P.S., and Holaday J.W. Selective kappa antagonist properties of nor-binaltorphimine in the rat MES seizure model. Life Sci 44 (1989) 661-665
255. Tortella F.C., Robles L., Echevarria E., Hunter J.C., and Hughes J. PD117302, a selective non-peptide opioid kappa agonist, protects against NMDA and maximal electroshock convulsions in rats. Life Sci 46 (1990) PL1-7
256. Tortella F.C., Robles L., and Holaday J.W. U50,488, a highly selective kappa opioid: anticonvulsant profile in rats. J Pharmacol Exp Ther 237 (1986) 49-53
257. Trujillo K.A., and Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 251 (1991) 85-87
258. Tsuda M., Suzuki T., Misawa M., and Nagase H. Involvement of the opioid system in the anxiolytic effect of diazepam in mice. Eur J Pharmacol 307 (1996) 7-14
259. Valentino R.J., Page M., Van Bockstaele E., and Aston-Jones G. Corticotropin-releasing factor innervation of the locus coeruleus region: distribution of fibers and sources of input. Neuroscience 48 (1992) 689-705
260. Van Bockstaele E.J., Gracy K.N., and Pickel V.M. Dynorphin-immunoreactive neurons in the rat nucleus accumbens: ultrastructure and synaptic input from terminals containing substance P and/or dynorphin. J Comp Neurol 351 (1995) 117-133
261. Vanderah T.W., Laughlin T., Lashbrook J.M., Nichols M.L., Wilcox G.L., Ossipov M.H., et al. Single intrathecal injections of dynorphin A or des-Tyr-dynorphins produce long-lasting allodynia in rats: blockade by MK-801 but not naloxone. Pain 68 (1996) 275-281
262. Ventriglia M., Bocchio Chiavetto L., Bonvicini C., Tura G.B., Bignotti S., Racagni G., et al. Allelic variation in the human prodynorphin gene promoter and schizophrenia. Neuropsychobiology 46 (2002) 17-21
263. Vincent S., Hokfelt T., Christensson I., and Terenius L. Immunohistochemical evidence for a dynorphin immunoreactive striato-nigral pathway. Eur J Pharmacol 85 (1982) 251-252
264. Vincent S.R., Hokfelt T., Christensson I., and Terenius L. Dynorphin-immunoreactive neurons in the central nervous system of the rat. Neurosci Lett 33 (1982) 185-190
265. Vlachakis N.D., De Guia D., Mendlowitz M., Antram S., and Wolf R.L. Hypertension and anxiety. A trial with epinephrine and norepinephrine infusion. Mt Sinai J Med 41 (1974) 615-625
266. VonVoigtlander P.F., Hall E.D., Ochoa M.C., Lewis R.A., and Triezenberg H.J. U-54494A: a unique anticonvulsant related to kappa opioid agonists. J Pharmacol Exp Ther 243 (1987) 542-547
267. VonVoigtlander P.F., Lahti R.A., and Ludens J.H. U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist. J Pharmacol Exp Ther 224 (1983) 7-12
268. Voorn P., van de Witte S.V., Li K., and Jonker A.J. Dynorphin displaces binding at the glycine site of the NMDA receptor in the rat striatum. Neurosci Lett 415 (2007) 55-58
269. Wagner J.J., Caudle R.M., and Chavkin C. Kappa-opioids decrease excitatory transmission in the dentate gyrus of the guinea pig hippocampus. J Neurosci 12 (1992) 132-141
270. Wagner J.J., Terman G.W., and Chavkin C. Endogenous dynorphins inhibit excitatory neurotransmission and block LTP induction in the hippocampus. Nature 363 (1993) 451-454
271. Wahlestedt C., Pich E.M., Koob G.F., Yee F., and Heilig M. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science 259 (1993) 528-531
272. Walker J.M., Moises H.C., Coy D.H., Baldrighi G., and Akil H. Nonopiate effects of dynorphin and des-Tyr-dynorphin. Science 218 (1982) 1136-1138
273. Wan W., Ennulat D.J., and Cohen B.M. Acute administration of typical and atypical antipsychotic drugs induces distinctive patterns of Fos expression in the rat forebrain. Brain Res 688 (1995) 95-104
274. Wang Z., Gardell L.R., Ossipov M.H., Vanderah T.W., Brennan M.B., Hochgeschwender U., et al. Pronociceptive actions of dynorphin maintain chronic neuropathic pain. J Neurosci 21 (2001) 1779-1786
275. Watkins L.R., Wiertelak E.P., and Maier S.F. Kappa opiate receptors mediate tail-shock induced antinociception at spinal levels. Brain Res 582 (1992) 1-9
276. Watson S.J., Khachaturian H., Taylor L., Fischli W., Goldstein A., and Akil H. Pro-dynorphin peptides are found in the same neurons throughout rat brain: immunocytochemical study. Proc Natl Acad Sci U S A 80 (1983) 891-894
277. Weber E., and Barchas J.D. Immunohistochemical distribution of dynorphin B in rat brain: relation to dynorphin A and alpha-neo-endorphin systems. Proc Natl Acad Sci U S A 80 (1983) 1125-1129
278. Weisskopf M.G., Zalutsky R.A., and Nicoll R.A. The opioid peptide dynorphin mediates heterosynaptic depression of hippocampal mossy fibre synapses and modulates long-term potentiation. Nature 362 (1993) 423-427
279. Werling L.L., Frattali A., Portoghese P.S., Takemori A.E., and Cox B.M. Kappa receptor regulation of dopamine release from striatum and cortex of rats and guinea pigs. J Pharmacol Exp Ther 246 (1988) 282-286
280. Westenberg H.G., den Boer J.A., and Kahn R.S. Psychopharmacology of anxiety disorders: on the role of serotonin in the treatment of anxiety states and phobic disorders. Psychopharmacol Bull 23 (1987) 145-149
281. Wilson C.J., and Groves P.M. Fine structure and synaptic connections of the common spiny neuron of the rat neostriatum: a study employing intracellular inject of horseradish peroxidase. J Comp Neurol 194 (1980) 599-615
282. Wise C.D., Berger B.D., and Stein L. Serotonin: a possible mediator of behavioral suppression induced by anxiety. Dis Nerv Syst 31 Suppl (1970) 34-37
283. Wittmann W., Schunk E., Rosskothen I., Gaburro S., Singewald N., Herzog H., et al. Prodynorphin-derived peptides are critical modulators of anxiety and regulate neurochemistry and corticosterone. Neuropsychopharmacology 34 (2009) 775-785
284. Woods A.S., Kaminski R., Oz M., Wang Y., Hauser K., Goody R., et al. Decoy peptides that bind dynorphin noncovalently prevent NMDA receptor-mediated neurotoxicity. J Proteome Res 5 (2006) 1017-1023
285. Xie C.W., Lee P.H., Douglass J., Crain B., and Hong J.S. Deep prepyriform cortex kindling differentially alters the levels of prodynorphin mRNA in rat hippocampus and striatum. Brain Res 495 (1989) 156-160
286. Xie C.W., Lee P.H., Takeuchi K., Owyang V., Li S.J., Douglass J., et al. Single or repeated electroconvulsive shocks alter the levels of prodynorphin and proenkephalin mRNAs in rat brain. Brain Res Mol Brain Res 6 (1989) 11-19
287. Yakovleva T., Bazov I., Cebers G., Marinova Z., Hara Y., Ahmed A., et al. Prodynorphin storage and processing in axon terminals and dendrites. FASEB J 20 (2006) 2124-2126
288. Yasuda K., Raynor K., Kong H., Breder C.D., Takeda J., Reisine T., et al. Cloning and functional comparison of kappa and delta opioid receptors from mouse brain. Proc Natl Acad Sci USA 90 (1993) 6736-6740
289. Yoshino H., Nakazawa T., Arakawa Y., Kaneko T., Tsuchiya Y., Matsunaga M., et al. Synthesis and structure-activity relationships of dynorphin A-(1-8) amide analogues. J Med Chem 33 (1990) 206-212
290. You Z.B., Herrera-Marschitz M., Nylander I., Goiny M., O'Connor W.T., Ungerstedt U., et al. The striatonigral dynorphin pathway of the rat studied with in vivo microdialysis-II. Effects of dopamine D1 and D2 receptor agonists. Neuroscience 63 (1994) 427-434
291. Young E., Walker J.M., Houghten R., and Akil H. [3H] dynorphin binding to guinea pig and rat brain. Life Sci 33 Suppl 1 (1983) 287-290
292. Young E.A., Walker J.M., Lewis M.E., Houghten R.A., Woods J.H., and Akil H. [3H]dynorphin A binding and kappa selectivity of prodynorphin peptides in rat, guinea-pig and monkey brain. Eur J Pharmacol 121 (1986) 355-365
293. Zamir N., Palkovits M., and Brownstein M.J. Distribution of immunoreactive dynorphin A1-8 in discrete nuclei of the rat brain: comparison with dynorphin A. Brain Res 307 (1984) 61-68
294. Zamir N., Palkovits M., and Brownstein M.J. Distribution of immunoreactive beta-neo-endorphin in discrete areas of the rat brain and pituitary gland: comparison with alpha-neo-endorphin. J Neurosci 4 (1984) 1248-1252
295. Zamir N., Palkovits M., and Brownstein M.J. The distribution of immunoreactive alpha-neo-endorphin in the central nervous system of the rat. J Neurosci 4 (1984) 1240-1247
296. Zamir N., Palkovits M., Weber E., and Brownstein M.J. Distribution of immunoreactive dynorphin B in discrete areas of the rat brain and spinal cord. Brain Res 300 (1984) 121-127
297. Zhang L., Peoples R.W., Oz M., Harvey-White J., Weight F.F., and Brauneis U. Potentiation of NMDA receptor-mediated responses by dynorphin at low extracellular glycine concentrations. J Neurophysiol 78 (1997) 582-590
298. Zhang H., Shi Y.G., Woods J.H., Watson S.J., and Ko M.C. Central kappa-opioid receptor-mediated antidepressant-like effects of nor-Binaltorphimine: behavioral and BDNF mRNA expression studies. Eur J Pharmacol 570 (2007) 89-96
299. Zhang S., Tong Y., Tian M., Dehaven R.N., Cortesburgos L., Mansson E., et al. Dynorphin A as a potential endogenous ligand for four members of the opioid receptor gene family. J Pharmacol Exp Ther 286 (1998) 136-141
300. Zhang A.Z., Zhou G.Z., Xi G.F., Gu N.F., Xia Z.Y., Yao J.L., et al. Lower CSF level of dynorphin(1-8) immunoreactivity in schizophrenic patients. Neuropeptides 5 (1985) 553-556
301. Zhu J., Chen C., Xue J.C., Kunapuli S., DeRiel J.K., and Liu-Chen L.Y. Cloning of a human kappa opioid receptor from the brain. Life Sci 56 (1995) PL201-7
302. Zhu J., Luo L.Y., Li J.G., Chen C., and Liu-Chen L.Y. Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands. J Pharmacol Exp Ther 282 (1997) 676-684